Platinib (Pujihua) complete Chinese instruction manual and important medication tips

Pralsetinib is an oral small molecule tyrosine kinase inhibitor that mainly targets tumors driven by RET (rearranged thyrotropin receptor) gene fusion or mutation. It is suitable for the treatment of RETfusion-positive patients with advanced or metastatic non-small cell lung cancer (NSCLC), thyroid cancer, and other RET driven solid tumors. As a new generation of precision targeted drugs, platinib has shown good clinical efficacy, but it is still necessary to strictly follow the instructions and pay attention to important medication tips during use to ensure efficacy and safety.

1. Indications and dosage

Platinib is indicated for adult patients with advanced or metastatic non-small cell lung cancer confirmed by molecular testing to be RET fusion or mutation positive, as well as certain patients with advanced thyroid cancer. The recommended dose is 400 mg orally once daily with or without food and continued until disease progression or unacceptable toxicity. In patients with hepatic impairment, mild to moderate hepatic dysfunction usually does not require dose adjustment, but patients with severe hepatic impairment should be used with caution under the guidance of a physician, and a dose reduction may be required. For patients with abnormal renal function, no dose adjustment is required for patients with mild to moderate renal impairment, but plasma concentrations and adverse reactions should be closely monitored in patients with severe renal impairment.

2. Adverse reactions and monitoring

Common adverse reactions of Platinib include hematological abnormalities (such as anemia, neutropenia), liver function abnormalities (ALT, ASTincreases), hypertension, abnormal heart rhythm, and mild to moderate gastrointestinal reactions (such as nausea, vomiting, diarrhea). In clinical use, it is recommended that patients undergo baseline blood routine, liver and kidney function and electrocardiogram examinations before treatment, and review them regularly during medication. If serious hematological or liver function abnormalities occur, the drug should be temporarily discontinued or the dose should be reduced, and symptomatic treatment should be carried out under the guidance of a doctor. At the same time, patients using platinib should monitor their blood pressure and take drug intervention to control hypertension if necessary.

3. Medication tips for special groups

Pregnant women, lactating women and patients of childbearing age must use strict contraception when using platinib. Use during pregnancy may have toxic effects on the fetus, and the drug may be excreted through breast milk during breastfeeding, so it is recommended to discontinue the drug or suspend breastfeeding. The safety in children and adolescent patients has not been fully established, and risks and benefits need to be evaluated under the guidance of professional doctors. Elderly patients generally tolerate it well, but should be appropriately monitored based on individual liver and kidney function and comorbid conditions.

4. Drug interactions and precautions

Platinib mainly passes through the liverCYP3A4Enzyme metabolism, during use should avoid combining with potent CYP3A inhibitors or inducers to prevent the blood concentration from increasing or decreasing, increasing toxicity or reducing efficacy. If combined use is necessary, the dosage should be adjusted under the guidance of a doctor and monitoring should be strengthened. Patients should regularly evaluate disease progression and side effects during treatment, and avoid discontinuing medication or adjusting dosage on their own. In terms of storage, the medicine should be placed in a dry and cool place, away from direct sunlight and out of the reach of children.

In general, platinib (Pralsetinib), as an innovative drug for RET targeted therapy, provides a new treatment option for patients with RET driven advanced or metastatic non-small cell lung cancer and related tumors. Strictly following medication instructions, regularly monitoring hematology, liver and kidney function, and paying attention to special populations and drug interactions are the keys to ensuring efficacy and safety. Patients should maintain close communication with their doctors during use and provide timely feedback on body reactions so that individualized dosage adjustments and adverse reaction management can be carried out to achieve the best therapeutic effect.

Reference link:https://www.drugs.com